Fluoguide AS
STO:FLUO
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Fluoguide AS
Operating Income
Fluoguide AS
Operating Income Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Operating Income | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
F
|
Fluoguide AS
STO:FLUO
|
Operating Income
-kr39.8m
|
CAGR 3-Years
-7%
|
CAGR 5-Years
-12%
|
CAGR 10-Years
N/A
|
|
|
Genmab A/S
CSE:GMAB
|
Operating Income
kr1.3B
|
CAGR 3-Years
12%
|
CAGR 5-Years
6%
|
CAGR 10-Years
28%
|
|
|
Zealand Pharma A/S
CSE:ZEAL
|
Operating Income
kr7.1B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Galecto Inc
NASDAQ:GLTO
|
Operating Income
-$16.9m
|
CAGR 3-Years
31%
|
CAGR 5-Years
5%
|
CAGR 10-Years
N/A
|
|
|
Ascendis Pharma A/S
NASDAQ:ASND
|
Operating Income
-€136.3m
|
CAGR 3-Years
38%
|
CAGR 5-Years
16%
|
CAGR 10-Years
-13%
|
|
|
B
|
Bavarian Nordic A/S
CSE:BAVA
|
Operating Income
kr1.8B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
35%
|
CAGR 10-Years
63%
|
|
Fluoguide AS
Glance View
FluoGuide A/S engages in the development of surgical solutions to reduce suffering for the patient and increase the likelihood of cure; as well as reducing costs for the health care system. The firm develops surgical solutions, which expected to reduce Cancer pain for the patient and increases the possibility of recovering as well as reducing costs for the health care system. The first product is the compound FG001, which lights up the cancer and its invasive growth into the surrounding tissue.
See Also
What is Fluoguide AS's Operating Income?
Operating Income
-39.8m
DKK
Based on the financial report for Dec 31, 2025, Fluoguide AS's Operating Income amounts to -39.8m DKK.
What is Fluoguide AS's Operating Income growth rate?
Operating Income CAGR 5Y
-12%
Over the last year, the Operating Income growth was -21%. The average annual Operating Income growth rates for Fluoguide AS have been -7% over the past three years , -12% over the past five years .
